Denmark slips into recession in third quarter
Denmark's economy entered a recession in the third quarter, as it recorded a second consecutive contraction owing do a slowdown in the pharmaceutical industry, official statistics showed Friday.
The country's gross domestic product shrank 0.7 percent between July and September compared to the previous three-month period, according to Statistics Denmark.
It followed a 0.7 percent drop in the second quarter, tipping the country into a technical recession, which is defined as two consecutive quarters of contraction.
"The decline in the third quarter was primarily due to a decline in manufacturing, with the pharmaceutical industry contributing to the decline," Statistics Denmark said in a statement.
Over the first six months of the year, Denmark's GDP had actually grown by 1.7 percent year-on-year.
This was in large part thanks to the pharmaceutical industry and in particular Novo Nordisk -- Europe's biggest company by market capitalisation -- which has seen a boost in sales of its anti-obesity treatments.
However, "today's figures show an increase in private consumption," noted Las Olsen, chief economist at Danske Bank, in a post on X, formerly Twitter.
"Income is rising even more. There is potential for more spending when and if consumer sentiment improves," Olsen continued.
Comments
See Also
The country's gross domestic product shrank 0.7 percent between July and September compared to the previous three-month period, according to Statistics Denmark.
It followed a 0.7 percent drop in the second quarter, tipping the country into a technical recession, which is defined as two consecutive quarters of contraction.
"The decline in the third quarter was primarily due to a decline in manufacturing, with the pharmaceutical industry contributing to the decline," Statistics Denmark said in a statement.
Over the first six months of the year, Denmark's GDP had actually grown by 1.7 percent year-on-year.
This was in large part thanks to the pharmaceutical industry and in particular Novo Nordisk -- Europe's biggest company by market capitalisation -- which has seen a boost in sales of its anti-obesity treatments.
However, "today's figures show an increase in private consumption," noted Las Olsen, chief economist at Danske Bank, in a post on X, formerly Twitter.
"Income is rising even more. There is potential for more spending when and if consumer sentiment improves," Olsen continued.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.